Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet

World Journal of Gastroenterology

Volumn 9, Issue 3, 2003, Pages 495-498

  Liang, Wei ^a   Wang, Hui ^a   Sun, Tie Mie ^a   Yao, Wen Qing ^a   Chen, Li Li ^a   Jin, Yu ^a   Li, Chun Ling ^a   Meng, Fan Juan ^a  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEWCASTLE DISEASE VACCINE; TUMOR CELL VACCINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG EFFICACY; FEMALE; GALLBLADDER CANCER; GASTROINTESTINAL CARCINOMA; HEAD CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER CANCER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PANCREAS CANCER; POSTOPERATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SKIN TEST; STOMACH CANCER; VACCINATION;

EID: 0037349751     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i3.495     Document Type: Article

References (36)

1. Mimori K, Mori M. Recent advances in the diagnosis and treatment of colorectal cancers. Nippon Geka Gakkai Zasshi 2002, 103: 468-471
2. Indar A, Maxwell-Armstrong CA, Durrant LG, Carmichael J, Scholefield JH. Current concepts in immunotherapy for the treatment of colorectal cancer. J R Coll Surg Edinb 2002; 47: 458-474
3. De Kleijn EM, Punt CJ. Biological therapy of colorectal cancer. Eur J Cancer 2002; 38: 1016-1022
4. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7: 3950-3962
5. Bartnes K. Tumor antigens presented to T helper lymphocytes-critical components of the cancer vaccine. Tidsskr Nor Laegeforen 2001; 121: 2941-2945
6. Zou SC, Qiu HS, Zhang CW, Tao HQ. A clinical and long-term follow-up study of peri-operative sequential triple therapy for gastric cancer. World J Gastroenterol 2000; 6: 284-286
7. Saeterdal I, Bjorheim J, Lislerud JA, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98: 13255-13260
8. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, Mansour E, Haller D G, Manola J, Hanna MG Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18: 148-157
9. Zeh HJ, Stavely-O'Carroll K, Choti MA. Vaccines for colorectal cancer. Trends Mol Med 2001; 7: 307-313
10. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001; 8: 389-401
11. Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, Monson JR, Guillou P, Calvert H, Carmichael J, Hardcastle JD. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001; 84: 1433-1436
12. Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 2001; 19: 2571-2575
13. Safa MM, Foon KA. Adjuvant immunotherapy for melanoma and colorectal cancers. Semin Oncol 2001; 28: 68-92
14. Foon KA. Immunotherapy for colorectal cancer. Curr Oncol Rep 2001; 3: 116-126
15. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen in advanced colorectal cancer. Clin Cancer Res 2000; 6: 4719-4724
16. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001; 48: 347-351
17. Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother 1999; 22: 251-259
18. Suh KW, Piantadosi S, Yazdi HA, Pardoll DM, Brem H, Choti MA. Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol 1999; 72: 218-224
19. Yamana H, Itoh K. Specific immunotherapy with cancer vaccines. Gann To Kagaku Ryoho 2000; 27: 1477-1488
20. Chen W, Rains N, Young D, Stubbs RS. Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer? J Gastroenterol Hepatol 2000; 15: 698-705
21. Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG. Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev 2000; 26: 169-190
22. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM. Phase I trial of intravenous administration of PV701, an oncolytic virus in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266
23. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 2001; 53: 39-46
24. Schirrmacher V. Anti-tumor vaccination. Zentralbl Chir 2000; 125 (SUPPL 1): 33-36
25. Zorn U, Duensing S, Langkopf F, Anastassiou G, Kirchner H, Hadam M, Knuver-Hopf J, Atzpodien J. Active specific immunotherapy of renal cell carcinoma: Cellular and humoral immune responses. Cancer Biother Radiopharm 1997; 12: 157-165
26. Sonoda K, Sakaguchi M, Okamura H, Yokogawa K, Tokunaga E, Tokiyoshi S, Kawaguchi Y, Hirai K. Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies. J Virol 2000; 74: 3217-3226
27. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhard R, Ertel C. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999; 6: 63-73
28. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1999; 19: 635-638
29. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 1998; 4: 783-794
30. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett 2001; 172: 27-36
31. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int J Oncol 2001; 18: 945-952
32. Zhang JK, Sun JL, Chen HB, Zeng Y, Qu YJ. Influence of granulocyte macrophage colony stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells. World J Gastroenterol 2000; 6: 718-720
33. Termeer CC, Schirrmacher V, Brocker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000; 7: 316-323
34. Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y, Qian Z. Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol 2000; 16: 363-373
35. Haas C, Ertel C, Gerhards R, Schirrmacher V. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle disease virus. Int J Oncol 1998; 13: 1105-1115
36. King DJ. A comparison of the onset of protection induced by Newcastle disease virus strain B1 and a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge. Avian Dis 1999; 43: 745-755